NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...

I got tested for the BRCA2 gene mutation after my mom was diagnosed with breast cancer. A simple test gave me peace of mind. After a breast-cancer diagnosis and a separate scare, my mom tested for the ...

Scientists at the Victor Chang Cardiac Research Institute have developed a world-first individualised risk prediction tool for people suffering from a type of heart arrhythmia that can cause sudden ...

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing. Stay ahead of policy, cost, and value—subscribe to AJMC ...

This Reading Room is a collaboration between MedPage Today® and: Patients who had genetic testing for BRCA mutations prior to breast cancer diagnosis had smaller tumors, less nodal involvement, and ...